BRIEF-Amgen, CytomX therapeutics announce strategic collaboration in Immuno-Oncology [Reuters]
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: Reuters
BRIEF-Amgen, CytomX therapeutics announce strategic collaboration in Immuno-Oncology | Reuters Reuters Staff 2 Min Read Oct 3 (Reuters) - Amgen Inc: * Amgen and CytomX Therapeutics announce strategic collaboration in immuno-oncology * Co will lead later development and commercialization with global late-stage development costs shared between co, CytomX * Under agreement, Co, CytomX to co-develop probody T-cell engaging bispecific against EGFRXCD3 with CytomX leading early development * Under agreement, co will make upfront payment of $40 million and purchase $20 million of cytomx common stock * CytomX will be eligible to receive up to $455 million in development, regulatory and commercial milestones for EGFR program * CytomX to be able to opt into profit share in U.S., receive tiered, double-digit royalties on sales outside of U.S. for EGFR program * Under agreement, Co will also receive exclusive worldwide rights to develop and commercialize up to three additional, undisclosed target
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX Therapeutics, Inc. (NASDAQ: CTMX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating.MarketBeat
- CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid TumorsGlobeNewswire
- CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas [Yahoo! Finance]Yahoo! Finance
CTMX
Earnings
- 11/7/23 - Beat
CTMX
Sec Filings
- 4/4/24 - Form DEFA14A
- 4/4/24 - Form DEF
- 3/28/24 - Form 4
- CTMX's page on the SEC website